Status:
COMPLETED
Arbitration Between Habitual and Goal-directed Behavior in Obsessive-compulsive Disorder: Circuit Dynamics and Effects of Noninvasive Neurostimulation
Lead Sponsor:
University of California, Los Angeles
Conditions:
OCD
Decision-Making
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
People utilize two behavioral strategies, goal-directed and habitual, when engaging in value-based decision-making that involves rewarding or punishing outcomes. Accumulating evidence suggests an imba...
Detailed Description
Investigators will recruit 30 male and female adults (age 18-65) with OCD and 30 age-, sex-, and education-matched healthy (medically, neurologically and psychiatrically) controls for this project. Ea...
Eligibility Criteria
Inclusion
- A) OCD participants inclusion criteria:
- DSM-5 diagnostic criteria for OCD as primary (most severe) diagnosis (based on the Mini International Neuropsychiatric Interview).
- Yale-Brown Obsessive-Compulsive Scale (YBOCS) total score is equal or greater than 16.
- unmediated or being on a stable dose of medication (only SSRIs and clomipramine) for at least 12 weeks prior to the study.
- fluent English speaker.
- signed informed consent.
- B) OCD participants exclusion criteria:
- IQ greater than 80 on the Wechsler Abbreviated Scales of Intelligence.
- lifetime DSM-5 diagnosis of mania, psychotic disorder, or substance dependence (per MINI).
- current DSM-5 diagnosis of MDD if Montgomery-Asberg Depression Scale (MADRS) scores are equal or greater than 35 (severe), or ADHD.
- taking any psychotropic medication other than SSRIs or clomipramine.
- severe psychiatric symptom that requires immediate inpatient psychiatric intervention such as suicidality.
- presence of any serious psychiatric, psychosocial, or neurological condition requiring immediate treatment.
- C) Healthy control inclusion criteria:
- 1-males and females age 18-65 years with signed informed consent and IQ greater than 80 on WASI.
- D) Exclusion criteria for all participants:
- presence of any MR scan contraindications particularly body metal or positive pregnancy test.
- medical conditions in which cerebral metabolism might be compromised such as thyroid disorders, diabetes or current tobacco smoking (potential effect on imaging endpoints).
- any history of seizure disorders.
Exclusion
Key Trial Info
Start Date :
July 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04075890
Start Date
July 15 2019
End Date
January 31 2024
Last Update
December 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States, 90095